Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q1 2025 value amounting to $674391.0.

  • China SXT Pharmaceuticals' Other Accumulated Expenses rose 8653.13% to $674391.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $674391.0, marking a year-over-year increase of 8653.13%. This contributed to the annual value of $674391.0 for FY2025, which is 8653.13% up from last year.
  • According to the latest figures from Q1 2025, China SXT Pharmaceuticals' Other Accumulated Expenses is $674391.0, which was up 8653.13% from $361543.0 recorded in Q1 2024.
  • In the past 5 years, China SXT Pharmaceuticals' Other Accumulated Expenses ranged from a high of $1.2 million in Q1 2022 and a low of $361543.0 during Q1 2024
  • Over the past 5 years, China SXT Pharmaceuticals' median Other Accumulated Expenses value was $789232.0 (recorded in 2023), while the average stood at $761430.6.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Other Accumulated Expenses skyrocketed by 18490.19% in 2021, and later plummeted by 5419.05% in 2024.
  • Quarter analysis of 5 years shows China SXT Pharmaceuticals' Other Accumulated Expenses stood at $819677.0 in 2021, then skyrocketed by 41.8% to $1.2 million in 2022, then crashed by 32.1% to $789232.0 in 2023, then crashed by 54.19% to $361543.0 in 2024, then surged by 86.53% to $674391.0 in 2025.
  • Its Other Accumulated Expenses stands at $674391.0 for Q1 2025, versus $361543.0 for Q1 2024 and $789232.0 for Q1 2023.